Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

Rhea-AI Summary

Dynavax (Nasdaq: DVAX) will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 2:10 p.m. ET. The presentation will be webcast and available on the company’s Investors > Events & Presentations page.

Dynavax is a commercial-stage biopharmaceutical company with two commercial products: HEPLISAV-B (Hepatitis B vaccine) and the CpG 1018 adjuvant, used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines.

News Market Reaction – DVAX

-2.26%

-2.26% Session close to close

In the Nov 20 session, DVAX declined 2.26%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m. ET.

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-at-the-8th-annual-evercore-healthcare-conference-302620786.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax (DVAX) present at the Evercore Healthcare Conference?

Dynavax will present on December 2, 2025 at 2:10 p.m. ET in a fireside chat.

How can investors watch Dynavax's (DVAX) Evercore presentation on December 2, 2025?

The presentation will be webcast and accessible via the Investors > Events & Presentations page on the company website.

What topics will Dynavax (DVAX) cover at the 8th Annual Evercore Healthcare Conference?

The company announced participation in a fireside chat; specific presentation topics were not disclosed.

What is Dynavax's (DVAX) ticker and industry?

Dynavax trades as Nasdaq: DVAX and is a commercial-stage biopharmaceutical company developing vaccines and adjuvants.

Which commercial products does Dynavax (DVAX) highlight ahead of the conference?

Dynavax highlights HEPLISAV-B vaccine and the CpG 1018 adjuvant.

Who can investors contact for more information about Dynavax's (DVAX) conference participation?

Investor/media contacts listed are Paul Cox and Nicole Arndt with the company-provided email and phone contacts.